Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 222

1.

Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment.

Soloway MS, Soloway CT, Eldefrawy A, Acosta K, Kava B, Manoharan M.

Eur Urol. 2010 Dec;58(6):831-5. doi: 10.1016/j.eururo.2010.08.027. Epub 2010 Aug 20.

PMID:
20800964
2.

Further support for active surveillance in the management of low-volume, low-grade prostate cancer.

Albertsen P.

Eur Urol. 2010 Dec;58(6):836-7. doi: 10.1016/j.eururo.2010.09.003. Epub 2010 Sep 15. No abstract available.

PMID:
20851512
3.

Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance.

San Francisco IF, Werner L, Regan MM, Garnick MB, Bubley G, DeWolf WC.

J Urol. 2011 Feb;185(2):471-6. doi: 10.1016/j.juro.2010.09.115. Epub 2010 Dec 17.

PMID:
21167525
4.

Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols.

Iremashvili V, Pelaez L, Manoharan M, Jorda M, Rosenberg DL, Soloway MS.

Eur Urol. 2012 Sep;62(3):462-8. doi: 10.1016/j.eururo.2012.03.011. Epub 2012 Mar 17.

PMID:
22445138
5.

Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study.

Stattin P, Holmberg E, Johansson JE, Holmberg L, Adolfsson J, Hugosson J; National Prostate Cancer Register (NPCR) of Sweden.

J Natl Cancer Inst. 2010 Jul 7;102(13):950-8. doi: 10.1093/jnci/djq154. Epub 2010 Jun 18.

6.

What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database.

Barocas DA, Cowan JE, Smith JA Jr, Carroll PR; CaPSURE Investigators.

J Urol. 2008 Oct;180(4):1330-4; discussion 1334-5. doi: 10.1016/j.juro.2008.06.019. Epub 2008 Aug 15.

PMID:
18707731
7.

Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial.

Godtman RA, Holmberg E, Khatami A, Stranne J, Hugosson J.

Eur Urol. 2013 Jan;63(1):101-7. doi: 10.1016/j.eururo.2012.08.066. Epub 2012 Sep 5.

PMID:
22980443
8.

EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.

Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F; European Association of Urology.

Eur Urol. 2011 Jan;59(1):61-71. doi: 10.1016/j.eururo.2010.10.039. Epub 2010 Oct 28.

PMID:
21056534
9.

Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer.

Capitanio U, Karakiewicz PI, Valiquette L, Perrotte P, Jeldres C, Briganti A, Gallina A, Suardi N, Cestari A, Guazzoni G, Salonia A, Montorsi F.

Urology. 2009 May;73(5):1087-91. doi: 10.1016/j.urology.2008.10.048. Epub 2009 Feb 4.

PMID:
19195695
10.

Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis.

Cooperberg MR, Broering JM, Carroll PR.

J Natl Cancer Inst. 2009 Jun 16;101(12):878-87. doi: 10.1093/jnci/djp122. Epub 2009 Jun 9.

11.

Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy.

Kulkarni GS, Lockwood G, Evans A, Toi A, Trachtenberg J, Jewett MA, Finelli A, Fleshner NE.

Cancer. 2007 Jun 15;109(12):2432-8.

12.

Optimizing patient selection for prostate monotherapy.

Lee AK, Schultz D, Renshaw AA, Richie JP, D'Amico AV.

Int J Radiat Oncol Biol Phys. 2001 Mar 1;49(3):673-7.

PMID:
11172948
14.

Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer.

Aizer AA, Paly JJ, Zietman AL, Nguyen PL, Beard CJ, Rao SK, Kaplan ID, Niemierko A, Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D'Amico AV, Efstathiou JA.

J Clin Oncol. 2012 Sep 1;30(25):3071-6. doi: 10.1200/JCO.2012.42.8466. Epub 2012 Jul 30.

PMID:
22851571
15.

Tumour grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer.

Ladjevardi S, Sandblom G, Berglund A, Varenhorst E.

Eur Urol. 2010 Apr;57(4):631-8. doi: 10.1016/j.eururo.2009.03.007. Epub 2009 Mar 10.

PMID:
19299069
16.
17.

Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance.

Roemeling S, Roobol MJ, Postma R, Gosselaar C, van der Kwast TH, Bangma CH, Schröder FH.

Eur Urol. 2006 Sep;50(3):475-82. Epub 2006 May 3.

PMID:
16713065
18.

Prostate biopsy: who, how and when. An update.

Djavan B, Milani S, Remzi M.

Can J Urol. 2005 Feb;12 Suppl 1:44-8; discussion 99-100. Review.

PMID:
15780165
19.

Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.

Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, Presti JC Jr; SEARCH Database Study Group.

J Urol. 2003 Jun;169(6):2136-41.

PMID:
12771735
20.

Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.

Kupelian PA, Katcher J, Levin HS, Klein EA.

Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1043-52.

PMID:
9169811

Supplemental Content

Support Center